Patent application number | Description | Published |
20130093122 | LIQUID SILANE-BASED COMPOSITIONS AND METHODS FOR PRODUCING SILICON-BASED MATERIALS - Described herein are synthesis schemes and methods for producing silicon based nanostructures and materials, including compositions and methods for synthesis of silicon-based nanowires and composites from three-component and four-component liquid silane/polymer inks. Materials and methods for producing silicon based micro and nanofibers that can be used in a variety of applications including material composites, electronic devices, sensors, photodetectors, batteries, ultracapacitors, and photosensitive substrates, and the like. | 04-18-2013 |
20150273510 | METHOD AND APPARATUS FOR AEROSOL DIRECT WRITE PRINTING - An aerosol deposition system that uses a liquid ink, fed directly to an ultrasonic source at or near a nozzle to form an aerosolized ink, which may be transported via a carrier gas to a sheath gas insertion location is presented. The sheath gas may direct or focus the atomized ink through a nozzle. Alternatively, a deposition head may be adapted to the ultrasonic source so that aerosolization of the ink occurs inside the deposition head, where the sheath gas flows around the ultrasonic source, transporting the aerosolized ink through a nozzle and toward a substrate ˜2 mm distant. The substrate may be translated to form features of controlled shape such as lines with widths from ≦30 μm to 100 μm. Variations of this system may yield systems where a carrier gas is unnecessary, and all aerosolized ink is transported via the sheath gas. | 10-01-2015 |
20160068691 | SILICON MATERIALS FROM THE PROCESSING OF LIQUID SILANES AND HETEROATOM ADDITIVES - Methods for forming silicon thin films and structures with incorporated metals, non-metals, and combinations thereof, liquid precursor compositions useful in such methods, and silicon thin films and structures with embedded heteroatom(s) are described. The compositions are generally liquid at ambient temperature and are comprised of liquid silane(s) and have metal and/or non-metal additives. Metal and non-metal sources include organometallic and organic compounds, respectively. The compositions may also contain a solvent. The compositions may be processed by printing, coating, or spraying onto a substrate and subjected to UV, thermal, IR, and/or laser treatment to form silicon films or structures with embedded heteroatom(s). | 03-10-2016 |
20160068954 | SYNTHESIS OF SILICON CONTAINING MATERIALS USING LIQUID HYDROSILANE COMPOSITIONS THROUGH DIRECT INJECTION - An apparatus and a non-vapor-pressure dependent method of chemical vapor deposition of Si based materials using direct injection of liquid hydrosilane(s) are presented. Liquid silane precursor solutions may also include metal, non-metal or metalloid dopants, nanomaterials and solvents. An illustrative apparatus has a precursor solution and carrier gas system, atomizer and deposit head with interior chamber and a hot plate supporting the substrate. Atomized liquid silane precursor solutions and carrier gas moves through a confined reaction zone that may be heated and the aerosol and vapor are deposited on a substrate to form a thin film. The substrate may be heated prior to deposition. The deposited film may be processed further with thermal or laser processing. | 03-10-2016 |
Patent application number | Description | Published |
20120035088 | LUBRICANT COMPOSITION HAVING IMPROVED ANTIWEAR PROPERTIES - The instant invention provides a lubricant composition having improved four-ball antiwear properties. The lubricant composition includes a base oil and one or more alkylethercarboxylic acid corrosion inhibitor(s) having the formula: | 02-09-2012 |
20140051621 | LUBRICANT COMPOSITION COMPRISING UNHINDERED ALKYL AMINES - A lubricant composition including a base oil and from 0.01 to 10 wt. % of an amine compound based on a total weight of the lubricant composition. The amine compound has the formula R | 02-20-2014 |
20140315767 | Seal Compatibility Additive To Improve Fluoropolymer Seal Compatibility of Lubricant Compositions - This disclosure is directed to an additive package for a lubricant composition that provides improved compatibility with fluoropolymer seals. The additive package comprises a seal compatibility additive. The disclosure is also directed to a lubricant composition comprising a base oil and a seal compatibility additive. The seal compatibility additive improves the compatibility with fluoropolymer seals of the resultant lubricant composition. | 10-23-2014 |
20140315768 | Seal Compatibility Additive To Improve Fluoropolymer Seal Compatibility of Lubricant Compositions - This disclosure is directed to an additive package for a lubricant composition that provides improved compatibility with fluoropolymer seals. The additive package comprises a seal compatibility additive. The disclosure is also directed to a lubricant composition comprising a base oil and a seal compatibility additive. The seal compatibility additive improves the compatibility with fluoropolymer seals of the resultant lubricant composition. | 10-23-2014 |
20140315769 | Lubricant Composition - A lubricant composition is substantially free of water and includes a base oil present in an amount of greater than 85 parts by weight per 100 parts by weight of the lubricant composition, includes an antioxidant, and includes one or more alkylethercarboxylic acid corrosion inhibitor(s) present in an amount of from 0.01 to 1 weight percent based on a total weight of said lubricant composition. The one or more alkylethercarboxylic acid corrosion inhibitor(s) have the formula; | 10-23-2014 |
20150191673 | Lubricating Oil Compositions Containing A Halide Seal Compatibility Additive And A Second Seal Compatibility Additive - This disclosure is directed to an additive package for a lubricant composition that provides improved fluoropolymer compatibility. The additive package comprises a halide seal compatibility additive and a second seal compatibility additive. The disclosure is also directed to a lubricant composition comprising a base oil, a halide seal compatibility additive, and a second seal compatibility additive. The halide seal compatibility and the second seal compatibility additive improves the fluoropolymer seal compatibility of the resultant lubricant composition. | 07-09-2015 |
20150210952 | Lubricant Composition Comprising Hindered Cyclic Amines - A lubricant composition includes a base oil and a cyclic amine compound. A method of lubricating a system including a fluoropolymer seal with the lubricant composition is also provided. An additive concentrate for a lubricant composition is also provided. The cyclic amine compound is useful for adjusting the total base number of a lubricant composition. The lubricant composition is compatible with fluoropolymer seals. | 07-30-2015 |
20150210956 | Lubricant Composition Comprising Acyclic Hindered Amines - A lubricant composition including an acyclic amine compound. A method of lubricating a system including a fluoro-polymer seal with the lubricant composition is also provided. An additive concentrate for a lubricant composition is also provided. The acyclic amine compound is useful for adjusting the total base number of a lubricant composition. The lubricant composition is compatible with fluoropolymer seals. | 07-30-2015 |
20160002560 | Sulfonate Esters To Improve Fluoropolymer Seal Compatibility Of Lubricant Compositions - This disclosure is directed to a lubricant composition having improved compatibility with fluoropolymer seals. The lubricant composition includes a base oil and a sulfonate ester. The disclosure is also directed to an additive package for a lubricant composition that provides improved compatibility with fluoropolymer seals. The additive package includes the sulfonate ester. The disclosure is also directed to a method of improving compatibility of a lubricant composition with a fluoropolymer seal disposed in an internal combustion engine. The sulfonate ester improves the compatibility with fluoropolymer seals of the resultant lubricant composition. | 01-07-2016 |
Patent application number | Description | Published |
20140106996 | Lubricant Compositions Comprising Boroxines and Sterically Hindered Amines To Improve Fluoropolymer Seal Compatibility - A lubricant composition including a boroxine compound is disclosed. A lubricant composition and additive package including a boroxine compound and a sterically hindered amine compound are also disclosed. A method of lubricating a system comprising a fluoropolymer seal with the lubricant composition is also disclosed. The boroxine compound of the lubricant composition acts to improve compatibility of the lubricant composition with a fluoropolymer seal. | 04-17-2014 |
20140106997 | Lubricant Compositions Comprising Boroxines and Amine Compounds To Improve Fluoropolymer Seal Compatibility - A lubricant composition including a boroxine compound is disclosed. A lubricant composition and additive package including a boroxine compound and an amine compound are also disclosed. A method of lubricating a system comprising a fluoropolymer seal with the lubricant composition is also disclosed. The boroxine compound of the lubricant composition acts to improve compatibility of the lubricant composition with a fluoropolymer seal. | 04-17-2014 |
20140142008 | Lubricant Compositions Comprising Epoxide Compounds - A lubricant composition including an epoxide compound is disclosed. An additive package including the epoxide compound is also disclosed. The epoxide compound of the lubricant composition acts to improve compatibility of the lubricant composition with a fluoropolymer seal and improve the total base number of the lubricant composition. | 05-22-2014 |
20140142009 | Lubricant Compositions Comprising Epoxide Compounds - A lubricant composition including an epoxide compound is disclosed. An additive package including the epoxide compound is also disclosed. The epoxide compound of the lubricant composition acts to improve compatibility of the lubricant composition with a fluoropolymer seal and improve the total base number of the lubricant composition. | 05-22-2014 |
20140142010 | Lubricant Compositions Comprising Epoxide Compounds - A lubricant composition including an epoxide compound is disclosed. An additive package including the epoxide compound is also disclosed. The epoxide compound of the lubricant composition acts to improve compatibility of the lubricant composition with a fluoropolymer seal and improve the total base number of the lubricant composition. | 05-22-2014 |
20140142011 | Lubricant Compositions Comprising Epoxide Compounds - A lubricant composition including an epoxide compound is disclosed. An additive package including the epoxide compound is also disclosed. The epoxide compound of the lubricant composition acts to improve compatibility of the lubricant composition with a fluoropolymer seal and improve the total base number of the lubricant composition. | 05-22-2014 |
20150045261 | Lubricant Compositions Comprising Trimethoxyboroxine To Improve Fluoropolymer Seal Compatibility - A lubricant composition including a boroxine compound is disclosed. An additive package including the boroxine compound is also disclosed. The boroxine compound of the lubricant composition acts to improve compatibility of the lubricant composition with a fluoropolymer seal. | 02-12-2015 |
20150045262 | Lubricant Compositions Comprising Trimethoxyboroxines and Amine Compounds To Improve Fluoropolymer Seal Compatibility - A lubricant composition including a boroxine compound is disclosed. An additive package including the boroxine compound is also disclosed. The lubricant composition and the additive package may additionally include an amine compound. The boroxine compound of the lubricant composition acts to improve compatibility of the lubricant composition with a fluoropolymer seal. | 02-12-2015 |
20150203783 | Polymer For Lubricant Compositions And Method Of Forming The Same - A polymer comprises a polymeric backbone, at least one piperidine ester moiety extending from the polymeric back-bone, and generally at least one C | 07-23-2015 |
20150344806 | Lubricant Compositions Comprising Trimethoxyboroxines and Sterically Hindered Amines To Improve Fluoropolymer Seal Compatibilty - A lubricant composition including a boroxine compound is disclosed. A lubricant composition and additive package including a boroxine compound and a sterically hindered amine compound are also disclosed. The boroxine compound of the lubricant composition acts to improve compatibility of the lubricant composition with a fluoropolymer seal. | 12-03-2015 |
Patent application number | Description | Published |
20080300593 | Method of Ablating Tissue - An electrocautery device is disclosed. In accordance with one aspect of the invention, the electrocautery electrode/tip is provided with a hollow, conductive tube terminating at its distal end in a ball point type tip. Fluid, preferably conductive fluid, is applied to the proximal end of the hollow electrode/tip, and expelled from the distal end thereof during electrocautery. The ball point distal tip allows the distal tip to be directly applied to the tissue and “rolled” or slid along the tissue. This allows the distal tip to be moved across the tissue without dragging or snagging on the tissue. In addition, the conductive fluid expelled from the distal tip further lubricates the distal tip as it moves across the tissue. If conductive fluid is used, the conductive fluid emanating from the electrode/tip conducts the RF electrocautery energy away from the distal tip so that it is primarily the fluid, rather than the distal tip that actually accomplishes the cauterizing of tissue. That is, the fluid serves as a “virtual” electrocautery electrode. Since it is the fluid, rather than the distal tip that cauterizes, coagulates and ablates, no burns or perforations are made to the tissue, reducing the amount of debris at the site. Also, the flow of fluid through the electrode/tip tends to keep the distal tip clean and cool. | 12-04-2008 |
20090189618 | METHOD, SYSTEM, AND APPARATUS FOR LIQUID MONITORING, ANALYSIS, AND IDENTIFICATION - Embodiments of liquid monitoring, analysis, and identification are described generally herein. Other embodiments may be described and claimed. | 07-30-2009 |
20100076299 | Inducing Desirable Temperature Effects On Body Tissue Using Alternate Energy Sources - A system for inducing desirable temperature effects on body tissue, the body tissue being disposed about a lumen. The system includes an elongate catheter having a proximal end and a distal end with an axis therebetween with an energy delivery portion for transmission of energy. A tissue analyzer configured to characterize the body tissue in the lumen proximate the energy delivery portion and an energy source coupled to the energy delivery portion transmitting tissue treatment energy, wherein the energy is non-RF energy. A processor coupled to the tissue analyzer and energy source, the processor configured to determine an appropriate treatment energy for the characterized body tissue so as to mildly heat the body tissue with the energy delivery portion without ablating. | 03-25-2010 |
20100168743 | Tuned RF energy for selective treatment of atheroma and other target tissues and/or structures - A catheter and catheter system can use energy tailored for remodeling and/or removal of target material along a body lumen, often of atherosclerotic material of a blood vessel of a patient. An elongate flexible catheter body with a radially expandable structure may have a plurality of electrodes or other electrosurgical energy delivery surfaces to radially engage atherosclerotic material when the structure expands. An atherosclerotic material detector system may measure and/or characterize the atherosclerotic material and its location, optionally using impedance monitoring. | 07-01-2010 |
20110130708 | Directional Delivery of Energy and Bioactives - Systems and methods are disclosed for the treatment of a target tissue by directionally delivering energy and/or bioactive materials to achieve a therapeutic effect. A balloon catheter system having a balloon portion and a plurality of electrodes may be energized to selectively deliver energy, bioactive materials, or a combination thereof to target tissue including tissues disposed about a lumen. The tissue may be targeted by applying energy, making tissue impedance analysis, and further selectively energizing electrodes through the use of an energy source with a controller. | 06-02-2011 |
20120157986 | Inducing desirable temperature effects on body tissue - Methods and systems are disclosed for treating diseased tissue by gentle heating. The method induces vasodilation on tissue disposed about an lumen having both healthy tissue and diseased tissue. The method includes coupling a probe surface to the luminal tissue at a target location and transmitting desired quantities of tissue remodeling energy from the coupled probe into each of a plurality of discrete remodeling zones in the luminal tissue so that the tissue remodeling energy heats the plurality of remodeling zones, the remodeling energy being configured to avoid muscular contraction and inhibit both acute and long-term occlusion of the lumen. | 06-21-2012 |
20120157988 | TUNED RF ENERGY FOR SELECTIVE TREATMENT OF ATHEROMA AND OTHER TARGET TISSUES AND/OR STRUCTURES - A catheter and catheter system can use energy tailored for remodeling and/or removal of target material along a body lumen, often of atherosclerotic material of a blood vessel of a patient. An elongate flexible catheter body with a radially expandable structure may have a plurality of electrodes or other electrosurgical energy delivery surfaces to radially engage atherosclerotic material when the structure expands. An atherosclerotic material detector system may measure and/or characterize the atherosclerotic material and its location, optionally using impedance monitoring. | 06-21-2012 |
20120157989 | TUNED RF ENERGY AND ELECTRICAL TISSUE CHARACTERIZATION FOR SELECTIVE TREATMENT OF TARGET TISSUES - A catheter and catheter system can use energy tailored for remodeling and/or removal of target material along a body lumen, often of atherosclerotic material of a blood vessel of a patient. An elongate flexible catheter body with a radially expandable structure may have a plurality of electrodes or other electrosurgical energy delivery surfaces to radially engage atherosclerotic material when the structure expands. An atherosclerotic material detector system may measure and/or characterize the atherosclerotic material and its location, optionally using impedance monitoring. | 06-21-2012 |
20120158101 | System for inducing desirable temperature effects on body tissue - A catheter and catheter system may be used to treat disease tissue by gentle heating in combination with gentle or standard dilation. An elongate flexible catheter body with a radially expandable balloon having a plurality of electrodes engage tissue including diseased tissue when the structure expands. | 06-21-2012 |
20140180196 | TUNED RF ENERGY AND ELECTRICAL TISSUE CHARACTERIZATION FOR SELECTIVE TREATMENT OF TARGET TISSUES - A catheter and catheter system can use energy tailored for remodeling and/or removal of target material along a body lumen, often of atherosclerotic material of a blood vessel of a patient. An elongate flexible catheter body with a radially expandable structure may have a plurality of electrodes or other electrosurgical energy delivery surfaces to radially engage atherosclerotic material when the structure expands. An atherosclerotic material detector system may measure and/or characterize the atherosclerotic material and its location, optionally using impedance monitoring. | 06-26-2014 |
Patent application number | Description | Published |
20080317760 | Compositions and Methods for Diagnosing and Treating Cancer - Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody. | 12-25-2008 |
20100317098 | Compositions and Methods for Diagnosing and Treating Cancer - The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth. | 12-16-2010 |
20110195065 | Compositions and Methods for Diagnosing and Treating Cancer - The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells. | 08-11-2011 |
20110311552 | NOTCH1 RECEPTOR BINDING AGENTS AND METHODS OF USE THEREOF - Means and methods for the diagnosis, characterization, prognosis and treatment of cancer, specifically targeting cancer stem cells are disclosed Provided is an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth, and a method of treating cancer comprising administering said antibody to a subject. | 12-22-2011 |
20130030155 | ANTIBODIES TO THE NOTCH1 RECEPTOR - The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells. | 01-31-2013 |
20130251705 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER - The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells. | 09-26-2013 |
20130273044 | Compositions and Methods for Diagnosing and Treating Cancer - The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth. | 10-17-2013 |
20140349399 | Compositions and Methods for Diagnosing and Treating Cancer - The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth. | 11-27-2014 |
20160053016 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER - The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells. | 02-25-2016 |
Patent application number | Description | Published |
20110165162 | Methods for Treating Cancers Comprising K-ras Mutations - Methods of inhibiting tumor growth, methods of treating cancer, and methods of reducing the frequency of cancer stem cells in a tumor are described. Particularly, the methods are directed to tumors or cancers that comprise a K-ras mutation. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described. | 07-07-2011 |
20120070438 | Methods for Treating Melanoma - Methods of inhibiting melanoma tumor growth, methods of treating melanoma and metastatic melanoma, and methods of reducing the frequency of tumor initiating cells (or cancer stem cells) in melanoma tumors are described. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described. | 03-22-2012 |
20140065149 | Methods for Treating Melanoma - Methods of inhibiting melanoma tumor growth, methods of treating melanoma and metastatic melanoma, and methods of reducing the frequency of tumor initiating cells (or cancer stem cells) in melanoma tumors are described. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described. | 03-06-2014 |
20150132301 | Combination Therapy for Treatment of Cancer - The present invention provides methods comprising combination therapy for treating cancer. In particular, the present invention provides Wnt pathway inhibitors in combination with MAPK pathway inhibitors for the treatment of cancer and other diseases. In some embodiments, the MAPK pathway signaling activation is due to a mutation in a MAPK pathway component. In some embodiments, the MAPK pathway signaling component is Ras, Raf, MEK, or ERK. | 05-14-2015 |
20150232570 | Methods of Treating Hematological Malignancies with Notch1 Antibodies - NOTCH1-binding antibodies and methods of using the antibodies for treating hematologic cancers are disclosed. Methods of using antibodies that bind to a non-ligand binding membrane proximal region of the extracellular domain of human NOTCH1 and methods of treating chronic lymphocytic leukemia (CLL), hairy cell leukemia, chronic myelogenous leukemia (CML), nonHodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or cutaneous T-cell lymphoma (CTCL) in a subject, comprising administering a therapeutically effective amount of a NOTCH1-binding antibody to the subject are also disclosed. Methods of identifying subjects suitable for such treatment methods are further disclosed. | 08-20-2015 |
20150316552 | Human Notch Receptor Mutations and Their Use - The present invention provides the identification and characterization of NOTCH mutations associated with enhanced receptor signaling. The present invention provides methods and kits for using the same. The present invention further provides methods of treating cancer in a patient having a solid tumor, wherein the solid tumor cells comprise an elevated level of NOTCH ICD. | 11-05-2015 |
Patent application number | Description | Published |
20100104574 | Frizzled-Binding Agents and Uses Thereof - Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. | 04-29-2010 |
20100111958 | Notch-Binding Agents and Antagonists and Methods of Use Thereof - The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth. | 05-06-2010 |
20110318341 | FRIZZLED-BINDING AGENTS AND USES THEREOF - Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. | 12-29-2011 |
20120288496 | Notch-Binding Agents and Antagonists and Methods of Use Thereof - The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth. | 11-15-2012 |
20120301489 | Jagged-Binding Agents and Uses Thereof - Antibodies that specifically bind to an extracellular domain of human Jagged 1 or human Jagged2 and modulate Jagged activity, and methods of using said antibodies to inhibit tumor growth are disclosed. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an anti-Jagged antibody to a patient having a tumor or cancer. | 11-29-2012 |
20130095116 | RSPO Binding Agents and Uses Thereof - The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer. | 04-18-2013 |
20130243774 | NOTCH1 BINDING AGENTS AND METHODS OF USE THEREOF - The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia. | 09-19-2013 |
20130252326 | FRIZZLED-BINDING AGENTS AND USES THEREOF - Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. | 09-26-2013 |
20130260455 | NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF - The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth. | 10-03-2013 |
20130266569 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER - An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody. | 10-10-2013 |
20130280277 | NOTCH1 RECEPTOR BINDING AGENTS AND METHODS OF USE THEREOF - The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth. | 10-24-2013 |
20130295105 | FRIZZLED-BINDING AGENTS AND USES THEREOF - Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. | 11-07-2013 |
20130295106 | Frizzled-Binding Agents And Uses Thereof - Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided. | 11-07-2013 |
20130296536 | NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF - The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth. | 11-07-2013 |
20130323265 | METHODS FOR TREATING CANCER WITH DLL4 ANTAGONISTS - The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a DLL4 antagonist. | 12-05-2013 |
20130323266 | METHODS FOR TREATING CANCER WITH NOTCH2/3 ANTIBODIES - The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a Notch2/3 antibody. | 12-05-2013 |
20140147443 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER - An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody. | 05-29-2014 |
20150197561 | JAGGED-BINDING AGENTS AND USES THEREOF - The present invention relates to Jagged-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of human Jagged1 or human Jagged2 and modulate Jagged activity. The present invention further provides methods of using agents that modulate the activity of Jagged, such as antibodies that specifically bind Jagged, and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer. | 07-16-2015 |
20150197563 | NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF - The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth. | 07-16-2015 |
20150232554 | FRIZZLED-BINDING AGENTS AND USES THEREOF - Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. | 08-20-2015 |
20160002344 | RSPO BINDING AGENTS AND USES THEREOF - The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer. | 01-07-2016 |
20160030561 | Methods of Treating Pancreatic Cancer - Novel methods of treating pancreatic cancer are provided. In one embodiment, the method comprises determining NOTCH mRNA expression levels in pancreatic cancer cells. In another embodiment, the method further comprises administering to a subject in need thereof a therapeutically effective dose of a NOTCH antagonist. | 02-04-2016 |